Author Archive
deCODE genetics introduces deCODEme Cardio and deCODEme Cancer
deCODE Complete Scan, Cardio Scan and Cancer Scan.
Through deCODEme™, the world’s first retail genome analysis service, deCODE genetics today announced the launch of the first focused genetic scans for assessing personal risk of several major cardiovascular diseases and common cancers. deCODEme Cardio™, which detects genetic risk factors for Heart Attack, Atrial Fibrillation, Peripheral Artery Disease (PAD), and several other conditions, is offered at an introductory price of $195. deCODEme Cancer measures genetic risk factors for Prostate Cancer, Lung Cancer, Bladder Cancer, Skin Cancer and Colorectal Cancers, as well as the common form of Breast Cancer, at an introductory price of $225. Both can be ordered as a bundle for $350.
deCODE to integrate new genetic risk factor for Type 2 Diabetes into its deCODEme™ Personal Genome Scan Service
Crown Prince Frederik of Denmark and Crown Princess Marie of Denmark along with deCODE scientist Unnur Thorsteinsdottir during an official visit to deCODE laboratories earlier this year.
Reykjavik, ICELAND, December 8, 2008 – deCODE genetics (Nasdaq:DCGN) today announced the discovery by an international consortium of scientists from deCODE and major European and US academic institutions of a single letter variation in the human genome (SNP) that is associated with increased fasting glucose levels and risk of type 2 diabetes (T2D). deCODE will employ its CLIA-registered genotyping laboratory and existing testing platform to swiftly integrate the finding into its deCODEme™ personal genome scan, and to assess the addition of this new variant to the company’s deCODE T2™ reference laboratory test for assessing individual risk of type 2 diabetes.
Read the rest of this entry »
